HomeCompareCAPV vs ABBV

CAPV vs ABBV: Dividend Comparison 2026

CAPV yields 37735.85% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAPV wins by $2.899018183866277e+22M in total portfolio value
10 years
CAPV
CAPV
● Live price
37735.85%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.899018183866277e+22M
Annual income
$28,839,841,157,070,980,000,000,000,000.00
Full CAPV calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CAPV vs ABBV

📍 CAPV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAPVABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAPV + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAPV pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAPV
Annual income on $10K today (after 15% tax)
$3,207,547.17/yr
After 10yr DRIP, annual income (after tax)
$24,513,864,983,510,330,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CAPV beats the other by $24,513,864,983,510,330,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAPV + ABBV for your $10,000?

CAPV: 50%ABBV: 50%
100% ABBV50/50100% CAPV
Portfolio after 10yr
$1.4495090919331385e+22M
Annual income
$14,419,920,578,535,490,000,000,000,000.00/yr
Blended yield
99.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CAPV
No analyst data
Altman Z
0.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAPV buys
0
ABBV buys
0
No recent congressional trades found for CAPV or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAPVABBV
Forward yield37735.85%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$2.899018183866277e+22M$102.3K
Annual income after 10y$28,839,841,157,070,980,000,000,000,000.00$24,771.77
Total dividends collected$2.8980301712208536e+22M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAPV vs ABBV ($10,000, DRIP)

YearCAPV PortfolioCAPV Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$3,784,285$3,773,584.91$11,550$430.00+$3.77MCAPV
2$1,338,658,568$1,334,609,383.06$13,472$627.96+$1338.65MCAPV
3$442,653,586,232$441,221,221,564.00$15,906$926.08+$442653.57MCAPV
4$136,827,293,163,315$136,353,653,826,047.36$19,071$1,382.55+$136827293.14MCAPV
5$39,536,928,536,407,864$39,390,523,332,723,110.00$23,302$2,095.81+$39536928536.38MCAPV
6$10,679,770,032,663,110,000$10,637,465,519,129,154,000.00$29,150$3,237.93+$10679770032663.08MCAPV
7$2,696,854,415,600,489,300,000$2,685,427,061,665,540,000,000.00$37,536$5,121.41+$2696854415600489.50MCAPV
8$636,646,159,211,682,600,000,000$633,760,524,986,990,000,000,000.00$50,079$8,338.38+$636646159211682688.00MCAPV
9$140,505,309,898,870,460,000,000,000$139,824,098,508,513,970,000,000,000.00$69,753$14,065.80+$140505309898870456320.00MCAPV
10$28,990,181,838,662,770,000,000,000,000$28,839,841,157,070,980,000,000,000,000.00$102,337$24,771.77+$2.899018183866277e+22MCAPV

CAPV vs ABBV: Complete Analysis 2026

CAPVStock

Cabo Verde Capital Inc. operates as a content streaming company. The company operates through three divisions: Distribution, Live Stream, and Studios & Productions. It has a streaming platform that has various channels, including sports, music, lifestyle, family, and comedy, as well as international based channels. The company is based in Las Vegas, Nevada.

Full CAPV Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CAPV vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAPV vs SCHDCAPV vs JEPICAPV vs OCAPV vs KOCAPV vs MAINCAPV vs JNJCAPV vs MRKCAPV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.